# OnCo record idea-alpha-first-mhspc (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-alpha-first-mhspc/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-alpha-first-mhspc" ;
  schema:name "Alpha-emitting PSMA therapy at first metastatic diagnosis"@en ;
  schema:description "If Pluvicto helps at first diagnosis, an alpha version might do more against microscopic disease, when tumour burden is smallest."@en ;
  schema:url <https://onco.cc/ideas/idea-alpha-first-mhspc/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04720157> ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/drugs/pluvicto/> ;
  onco:terms <https://onco.cc/terms/alpha-vs-beta/>, <https://onco.cc/terms/dosimetry/> ;
  onco:trials <https://onco.cc/trials/psmaddition/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025/>, <https://onco.cc/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/> .